High-grade glioma pediatric · 1 regimen
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Temozolomide monotherapy Variant #02 | — | R 7 358 | 14d | ~4.0 mo | ~16.3 mo | ~26 | ~R 129 994 PFS proxy · indirect | 10 |
1 of 1 regimen shown